19 March 2019 | News
Expansion projects will increase capacity to meet growing customer demand for biologics
Thermo Fisher Scientific Inc., the world leader in serving science, has announced that it is investing $150 million in its Pharma Services business to provide additional capacity for sterile liquid and lyophilized product development and commercial manufacturing.
Included in the site expansion projects are Monza and Ferentino, Italy, and Greenville, North Carolina. In response to customer requests, each of the sites will be equipped with aseptic filling lines and isolator technology. Construction is expected to be completed within the next 24 months.
"These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise," said Michel Lagarde, president of pharma services for Thermo Fisher Scientific. "We continue to invest to expand our capabilities and help our customers deliver the highest quality medicines to the patients who need them."